In a report dated May 30, Morgan Stanley analyst Vikram Purohit reaffirmed his Buy rating on Axsome Therapeutics Inc. (NASDAQ ...

Shares of IBD 50 stock Axsome Therapeutics tumbled Tuesday after the biotech reported mixed results for its drug, Sunosi, in adults with attention deficit hyperactivity disorder. The company ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...

Axsome Therapeutics' current portfolio could generate over $3 billion in peak annual sales. However, that won't happen for several years. The company has other exciting pipeline candidates.

Axsome Therapeutics, Inc. has announced a settlement with Hetero Labs Ltd. regarding patent litigation over its product SUNOSI® (solriamfetol). The litigation arose from Hetero's application to ...

Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m, up 81% YoY, but net loss increased to $(64.6m). Despite positive market response and promising pipeline candidates ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year growth Auvelity ® 4Q and full year 2024 net product ...

HC Wainwright reissued their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report report published on Thursday morning,Benzinga reports. They currently ...

Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics, said, “Today’s approval of SYMBRAVO marks an important milestone for the migraine community by providing a rationally ...

State of New Jersey Common Pension Fund D decreased its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 1.9% during the 4th quarter, HoldingsChannel reports.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the first ...